Actively Recruiting
Manipulating E-Cigarette Nicotine to Promote Public Health
Led by Ohio State University Comprehensive Cancer Center · Updated on 2026-05-13
375
Participants Needed
1
Research Sites
156 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This clinical trial explores the manipulation of e-cigarette (EC) nicotine to promote public health. Researchers are trying to understand and gather information about how the strength, form, and structure of nicotine in products play a significant role in their potential for addiction and how they might affect health risks. The information gained from this study may allow researchers to understand how these aspects of nicotine influence the potential for addiction, how people puff on ECs, how the body processes nicotine, and any potential harmful effects it might have on health. Exploring these specific characteristics of nicotine may also determine if an EC product standard could help identify optimal nicotine levels for users.
CONDITIONS
Official Title
Manipulating E-Cigarette Nicotine to Promote Public Health
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Current exclusive young adult e-cigarette user for at least 3 months, aged 21-24, with minimal smoking history (10 or fewer cigarettes in lifetime)
- Current older adult smoker aged 25-65, daily smoker with 100 or more cigarettes in lifetime, interested in trying e-cigarettes
- Willing to abstain from nicotine, tobacco, and marijuana for at least 12 hours before Study 1 visits and 2 hours before Study 2 visits
- Able to read, write, and speak English
You will not qualify if you...
- Currently trying to quit nicotine or tobacco products
- Currently pregnant, planning pregnancy, or breastfeeding
- If aged 21-24 and use tobacco products other than e-cigarettes beyond specified limits (more than 10 cigarettes, cigars, or smokeless tobacco uses, or hookah in last 30 days)
- Diagnosis of lung diseases such as asthma, cystic fibrosis, or chronic obstructive pulmonary disease
- New or unstable cardiovascular disease diagnosed within past 3 months
- Use of medications that induce CYP2A6 enzyme (e.g., rifampicin, dexamethasone, phenobarbital, anti-convulsion drugs)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States, 43210
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
FACTORIAL
Primary Purpose
PREVENTION
Number of Arms
28
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here